Table 1 Baseline characteristics of the study population and events during follow-up
n (%), [IQR] | |
|---|---|
Patients included | 85 |
Baseline characteristics | |
Age, years | 62 [49–75] |
Female sex | 25 (29) |
SAPS II | 41 [25–57] |
BMI, kg/m2 | 32 [25–39] |
Hypertension | 51 (60) |
Diabetes | 33 (39) |
Cardiomyopathy | 23 (27) |
Chronic kidney failure | 17 (20) |
Active Smoking | 13 (15) |
COPD | 14 (16) |
Chronic respiratory insufficiency | 18 (21) |
Sars-CoV-2 vaccination | 16 (19) |
Tomodensitometry findings | |
Percentage of pulmonary infiltrate | |
0–25% | 6 (7) |
26–50% | 27 (32) |
51–75% | 30 (35) |
> 75% | 22 (26) |
Pulmonary embolism | 12 (14) |
Treatments before invasive mechanical ventilation | |
High-flow nasal oxygen | 28 (33) |
Non-invasive ventilation | 55 (65) |
Dexamethasone | 85 (100) |
Tocilizumab | 6 (7) |
Nirmatrelvir/ritonavir | 1 (1) |
Tixagevimab/cilgavimab | 2 (2) |
Remdesivir | 2 (2) |
Intensive care unit | |
Neuromuscular agent blockade | 85 (100) |
Inhaled NO | 24 (28) |
Renal replacement therapy | 20 (24) |
VV-ECMO* | 5 (6) |
Norepinehrine | 50 (59) |
Duration of prone position, h | 18 [16–20] |
Prone position sessions | 5 [1–9] |
Duration of invasive mechanical ventilation, d | 27 [7–47] |
Length of ICU stay, d | 30 [9–51] |
Day 90 mortality | 37 (44) |
Day 90 ventilatory-free days alive | 34 (29) |